Cancer treatment breakthrough? timing your therapy could be key
NCT ID NCT07224971
Summary
This study is testing whether giving standard immunotherapy in the morning versus the afternoon makes it work better for patients with advanced cancer. It will enroll 350 people with advanced lung cancer or other solid tumors who are starting immunotherapy for the first time. Participants will be randomly assigned to receive their treatment either before 11 AM or after 12 PM to see if the timing affects how long the cancer stays under control and patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.